EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries

PROVIDENCE, R.I., April 7, 2020 /PRNewswire/ -- EpiVax, Inc., is using advanced computational tools to accelerate a COVID-19 vaccine candidate (EPV-CoV19) for healthcare workers (HCW) into clinical trials in 6 months. Today, EpiVax announces its partnership with GAIA Vaccine Foundation ("GVF") to crowd-source funds for the project and its pledge to make a free license available to developing countries who qualify, in the context of this partnership.

EPV-CoV19 is a peptide-based, epitope-driven vaccine that can be rapidly and safely produced in most countries. Applying EpiVax's expertise enabled the selection of sequences representing all circulating SARS-CoV-2 genomes that will drive a T cell-mediated immune response, providing HCW with immune system "body armor", reducing their risk of morbidity and mortality. EPV-CoV19 will enter US clinical trials once funds have been raised ($1.75M).

GVF, a 501(c)(3) nonprofit organization, will enable private citizens and foundations to contribute to development of EPV-CoV19. GVF's mission is to reduce incidence of infectious diseases that disproportionately affect the under-served and promote the development of globally relevant, accessible vaccines that can be distributed on a not-for-profit basis in the developing world. Annie De Groot, MD, EpiVax CEO/CSO, states "The soul of each company will be revealed during this crisis. Personally, I do not believe this is the time to become a billionaire. Each of us should do what we do best to reduce the impact of COVID-19 globally." As it is the mission of EpiVax to "improve human health everywhere", the company has granted GVF a cost-free, royalty-free license to the EPV-CoV19 design for use in countries that can produce and test the vaccine candidate on the Least Developed Countries list published by the United Nations. Collaborators and a clinical trial site in West Africa have been identified.

Donations to the GVF COVID-19 vaccine fund will be entirely dedicated to the preclinical and clinical development phases of EPV-CoV19.

For more information or to make a donation to the program, visit http://www.gaiavaccine.org/covid19.

About EpiVax:
EpiVax is a biotechnology company with a broad portfolio of projects, including vaccines and immunotherapies for infectious diseases, autoimmunity and cancer. www.epivax.com

About GVF:
GVF is a 501(c)(3) organization that supports activities to advance healthcare accessibility and educational programs to inform the public about diseases, including HIV, and the importance of vaccines in West Africa. www.gaiavaccine.org       

Press Contact:
Annie De Groot, MD, EpiVax
401-272-2123
[email protected] 

SOURCE EpiVax Inc.